The roadmap for antipsychotic psychopharmacology: An overview

Journal of Clinical Psychiatry

Volumn 68, Issue 11, 2007, Pages 1799-1806

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; BINDING AFFINITY; BLURRED VISION; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; CONSTIPATION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOTENSION; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; OUTCOME ASSESSMENT; PARKINSONISM; POSITIONAL DIZZINESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

EID: 37049015758     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1121     Document Type: Review

References (52)

1. Weiden PJ, Preskorn SH, Fahnestock PA, et al. Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap. J Clin Psychiatry 2007;68(suppl 7):1-48
2. The President's New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America. Final Report. Dept Health Human Services Publication No SMA-03-3832. Rockville, Md: July 2003 (available at www.mentalhealthcommission.gov/reports/finalreport/fullreport-02.htm)
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd ed. Am J Psychiatry 2004;161(suppl 2):1-56
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder (rev). Am J Psychiatry 2002;159(suppl 4):1-50
5. Kane JM, Leucht S, Carpenter D, et al. The Expert Consensus Guideline Series: Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):5-19
6. Keck PE, Perlis RH, Otto MW, et al. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgrad Med Spec Rep 2004:1-120
7. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272
8. Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull 2006;32:432-442
9. Preskorn SH. The slippery slide. J Pract Psychiatry Behav Health 1999;5:50-55
10. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions, pt 1. J Psychiatr Pract 2003;9:376-384
11. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1711
12. Preskorn SH. Defining "is." J Pract Psychiatry Behav Health 1999;5:224-228
13. Nyberg S, Farde L, Halldin C. Test-retest reliability of central [11C]raclopride binding at high D2 receptor occupancy. Psychiatry Res 1996;67:163-171
14. Ability [package insert]. Princeton, NJ: Bristol-Meyers Squibb Co; 2006
15. Weiden PJ. Switching in the era of atypical antipsychotics: an updated review. Postgrad Med 2006; Spec No: 27-44
16. Richelson E. Pharmacology of antidepressants. Mayo Clinic Proceedings 1994;69:1069-1081
17. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? Neuropsychopharmacology 1998;18:63-101
18. Bymaster FP, Hemrick-Luecke SK, Perry KW, et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl) 1996;124:87-94
19. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
20. Levy RH, Thummel KE, Trager WF, et al. Metabolic Drug Interactions. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2000
21. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27
22. Preskorn SH, Flockhart DA. 2006 guide to psychiatric drug interactions. Prim Psychiatry 2006;13:35-64
23. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Arch Gen Psychiatry 2005;62:975-983
24. Ziedonis DM, Smelson D, Rosenthal RN, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-339
25. Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006;7:1871-1885
26. Arango C, Parellada M, Moreno DM. Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 2004;14(suppl 4):S471-S479
27. Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsvchotic agents in older patients. J Clin Psychiatry 2004;65(suppl 2):5-99
28. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system, pt 1. J Psychiatr Pract 2005;11:5-15
29. Alexopoulos GS, Jeste DV, Chung H, et al. The expert consensus guideline series: treatment of dementia and its behavioral disturbances: introduction: methods, commentary, and summary. Postgrad Med 2005; Spec No:6-22
30. Aichhorn W, Whitworth AB, Weiss EM, et al. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006;29:587-598
31. Colton CW, Manderscheid RW. Congruences in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006;3:A42
32. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain. Am J Psychiatry 1999;156:1686-1696
33. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000;321:483-484
34. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002;63:207-213
35. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45-53
36. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
37. Uçok A, Polat A, Bozkurt O, et al. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004;58:434-437
38. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847
39. Houseknecht K, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats. Neuropsychopharmacology 2007;32:289-297
40. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
41. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-491
42. Banerji MA, Lebowitz J, Chaiken RL, et al. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997;273:E425-E432
43. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
44. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622
45. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:1837-1847
46. Jody D, Saha AR, Iwamoto T. Meta-analysis of weight effects with aripiprazole. Int J Neuropsychopharmacol 2002;5(suppl 1):S186
47. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006;62:1049-1053
48. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24
49. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007;20:131-137
50. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-763
51. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: systematic review. Br J Psychiatry 2006;189:102-108
52. Covell NH, Jackson CT, Weissman EM. Health monitoring for patients who have schizophrenia: summary of the Mount Sinai Conference recommendations. Postgrad Med 2006; Spec No: 20-26 Novartis, Organon, Otsuka, Pfizer, Solvay, Somerset, Sumitomo, Wyeth, and Yamanouchi.